yeztugo hiv - Search News

News

HIV, CVS Health and Yeztugo

For now, CVS declines to cover Gilead's long-acting HIV PrEP treatment Yeztugo

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV prevention breakthrough, at least for now. | CVS Health, the parent of PBM juggernaut CVS Caremark,

· 1d · on MSN

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.

· 11h

GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo

Seeking Alpha1mon

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for ...

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025 Jul. 14, 2025 9:30 AM ET Gilead Sciences, Inc. (GILD) ...

WAPT2mon

Twice-a-year HIV prevention shot Yeztugo could be a game changer for ...

JACKSON, Miss. — The FDA has approved Yeztugo, the world’s first twice-a-year shot to prevent HIV infection, marking a significant advancement in HIV prevention. The new treatment is expected to ...

Nasdaq2mon

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV ...

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved Yeztugo ®— the company’ s injectable HIV-1 capsid inhibitor— as pre-exposure prophylaxis to ...

From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results